SCHEMBL4589289

SCHEMBL4589289

N=C(N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)[O-].N=C(N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)[O-].[Mn+2]

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ NMT1 P30419 5/20 0.42
▸ NMT2 O60551 4/20 0.42
▸ SLC15A2 Q16348 1/20 0.42
▸ NPY4R P50391 9/20 0.41
▸ NPY5R Q15761 9/20 0.41
▸ NPY1R P25929 8/20 0.41
▸ NPY2R P49146 6/20 0.41
▸ SIRT6 Q8N6T7 1/20 0.40
▸ SIRT1 Q96EB6 1/20 0.40
▸ TLR2 O60603 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2241867 0.98 NMT1 (0.42) NMT1NMT2SLC15A2NPY4RNPY5R
SCHEMBL4587709 0.90 NPY4R (0.36) SLC15A2NPY4RNPY5RNPY1RNPY2R
SCHEMBL29516817 0.89 TLR2 (0.48) NMT1NMT2NPY4RNPY5RNPY1R
SCHEMBL5086123 0.89 NMT2 (0.42) NMT1NMT2NPY4RNPY5RNPY1R
SCHEMBL30373028 0.88 SLC15A2 (0.51) NMT1NMT2SLC15A2NPY4RNPY5R
SCHEMBL30713830 0.88 SLC15A2 (0.51) NMT1NMT2SLC15A2NPY4RNPY5R
SCHEMBL31106970 0.88 SLC15A2 (0.51) NMT1NMT2SLC15A2NPY4RNPY5R
SCHEMBL29461533 0.88 SLC15A2 (0.51) NMT1NMT2SLC15A2NPY4RNPY5R
SCHEMBL31717990 0.88 SLC15A2 (0.51) NMT1NMT2SLC15A2NPY4RNPY5R
SCHEMBL30372694 0.88 SLC15A2 (0.51) NMT1NMT2SLC15A2NPY4RNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2008-10-16 — — US disclosed
US-7384916-B2 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2008-06-10 — — US disclosed
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2006-11-02 — — US disclosed
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin PROCYTE CORPORATION (US) 2006-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin RBP1, RBP4, SOD1 NMT1 2143/4885NMT2 2250/4885SLC15A2 2656/4885
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin RBP1, RBP4, MC1R NMT1 2565/4885NMT2 2577/4885SLC15A2 1582/4885
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN RBP1, RBP4, SOD1 NMT1 2143/4885NMT2 2250/4885SLC15A2 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback